TS Wiley Lecture at the AustrailAsian Academy of Anti-Aging Medicine

Sep 30, 2009 14:22 ET

SANTA BARBARA, CA--(Marketwire - September 30, 2009) -TS Wiley talked about menopause and andropause for both sexes along with the benefits of rhythmic, bioidentical hormone replacement therapy (BHRT) to a medical audience actively involved in anti-aging, preventive, regenerative and aesthetic medicine.

"Unfortunately, the current state of BHRT for menopausal women does not address the correct scientific template to affect real recovery," said T.S. Wiley, author and founder of the Wiley Protocol. "Creating a BHRT regimen that does not fully restore complete replacement values and menses seems as if it would further derange the template of hormonal and environmental interrelatedness that has evolved over millennia."

Wiley's approach to Bioidentical Hormone Replacement Therapy (BHRT) is rhythmic, or biomimetic hormone replacement for menopausal women who experience mood swings, foggy thinking, anxiety, night sweats, sleeplessness, depression and/or lack of libido. It employs plant derived hormones dosed in escalating and descending biomimetic curves.

The latest research on bioidentical hormone replacement therapy suggests that women must cycle their hormones and have a menstrual bleed to be truly safe from cardiovascular events. According to a recent Danish study on 700,000 women, a combined cyclic regimen of bioidenticals with monthly bleeding creates a lower cardiovascular risk for women than continuous-combined estrogen, progesterone, and progestin therapy, which does not provide menses. Current standards for BHRT are the same as synthetics -- statically dosed, continuous-combined, which does not intend to provide a menstrual period.

She continued, "Bearing this in mind, consider a new approach to BHRT, including a protocol which provides women with a more accurate form of restoration for lost endocrine function at the steroid receptor level as well as effecting the physiologic functional medicine approach. The components of this transdermal protocol and the amount of hormones women take vary throughout the female 28-day cycle to mimic the hormone levels of a woman in her prime."

T.S. Wiley is the developer of The Wiley Protocol® rhythmic, compounded bioidentical hormones, and has pioneered the standardization of the patent pending Wiley Protocol formulations using unique, standardized compounding procedures and color coded packaging, available to physicians and patients at recommended retail prices. The company's biomimetic hormone protocols must be formulated by a trained and registered compounding pharmacist.

Wiley Systems, Inc distributes the following biomimetic dosing schedules: The Wiley Protocol™ for Women; Wiley Protocol for Men™, biomimetic DHEA and testosterone restoration; Wiley Protocol Thyroid™ for Women, biomimetic thyroid hormone restoration; Wiley Protocol Testosterone™ for Women, biomimetic testosterone restoration; and Wiley Protocol Face Crème™, which promotes a more youthful appearance by filling in fine lines with the body's own adiposities.

T.S. Wiley is a medical theorist in environmental endocrinology and Darwinian medicine, and has residences in both Santa Fe, New Mexico and Santa Barbara, California. She is a noted writer, researcher and lecturer on the effects of hormones, particularly in menopausal women as well as an accepted expert in chronobiology and circadian rhythmicity. Wiley's environmental endocrinology seminars, "Two Days Back on Earth" in Glendale, California are attended by physicians from around the world.

About Wiley Systems, Inc. and the Wiley Protocol. The Wiley Systems, Inc. was founded in 2005 in Santa Barbara, California by T.S. Wiley, who is the developer of the Wiley Protocol®, a trademarked patent pending delivery system consisting of the biomimetic, bioidentical hormones estradiol and progesterone, or biomimetic hormone restoration therapy. Wiley Systems began as a project to fund the union of doctors and pharmacists in a common goal to standardize bioidentical hormones for academic research. Now in 2009, the Wiley Pharmacy Consortium numbers around 50 pharmacies and more than 250 doctors prescribing in the US and Canada.

The Wiley Protocol is only available at compounding pharmacies that have joined the project for future National Institutes of Health (NIH) study and have contractually agreed to the standardized methods, materials, packaging and recommended pricing. In exchange, Wiley Systems provides intellectual property and provides 28WP logo-bearing packaging consisting of color-coded bags and applicators. The Wiley Protocol name assures customers that they are receiving authentic Wiley Protocol dosing rhythms based on original research.